드림씨아이에스

223250KOSDAQ

71.9 / 100

Reference Date: 2026-09-08

Financial Score29.5 / 40

News Sentiment20.4 / 25

Momentum10.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

DreamCIS is a Contract Research Organization (CRO) that provides comprehensive services such as clinical trial design, data management, statistical analysis, and regulatory submissions for pharmaceutical companies. With over 25 years of experience and global expansion, the company is addressing growing demand for high-value drug development, including gene therapies and next-generation treatments.

Number of Employees

395people

Average Salary

55.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

11.30Industry Average 15.005.0Point

In line with industry avg

PBR

0.97Industry Average 1.204.0Point

In line with industry avg

ROE

9.25Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

2.75Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲18.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲111.0% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 8.2% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 81.7

Positive
드림씨아이에스, 12개 바이오벤처 이끌고 中 항저우 상륙
드림씨아이에스의 중국 진출로 인해 글로벌 바이오 시장에서의 영향력 확대 기대.
Positive
"中 규제기관 '동물대체시험법' 채택"…드림씨아이에스·큐리바이오,...
큐리바이오의 혁신적인 오가노이드 기술이 중국의 규제기관의 지원으로 글로벌 바이오 시장에서의 경쟁력을 강화할 것으로 예상됩니다.
Positive
임상수탁 기업들 상반기 외형 회복…수익성 '양극화'
드림씨아이에스는 임상수탁 분야에서 상반기 매출 회복을 보이며 긍정적인 성장세를 유지하고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 3,380Won52-week high 7,69052-week low 2,450

1-month return3.0Point

1m -0.29% (flat)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 1Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-13
Positive[기재정정]단일판매ㆍ공급계약체결2026-08-11